<DOC>
	<DOC>NCT00423891</DOC>
	<brief_summary>The purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. Safety, tolerability and efficacy will also be studied</brief_summary>
	<brief_title>A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>218 years of age Group A: Lamivudine naive (&lt;1 week of Lamivudine) and not within 24 weeks of screening; Group B: Lamivudine experienced (&gt; 12 weeks of Lamivudine); Group C: nucleoside/nucleotide experienced (&gt; 12 weeks of nucleoside/tide therapy) added as a countryspecific protocol amendment (not all sites had Group C). HBV Deoxyribonucleic acid (DNA) ≥ 100000 copies/mL; ≥ 10000 copies for nucleoside/nucleotide experienced (Group C) Detectable Hepatitis B surface antigen (HBsAg) for 24 weeks prior to screening Hepatitis B e antigen (HBeAg) positive Compensated liver and renal function Elevated alanine aminotransferase (ALT) at screening and during the 24 weeks prior to screening (for Groups A and B) Coinfection with Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis D Virus (HDV) Children who were breastfed while their mother received Lamivudine, or children whose mothers received Lamivudine during pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>